Protein kinase C activation and its role in kidney disease (review article)

Nephrology

Volumn 11, Issue 5, 2006, Pages 428-434

  Li, Jun ^a   Gobe, Glenda ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Diabetic nephropathy; Kidney cancer; Protein activation; Protein kinase C; Renal cell carcinoma

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ANGIOTENSIN 2 RECEPTOR; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYTOKINE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE REDUCTASE; INTERCELLULAR ADHESION MOLECULE 1; ISIS 3521; ISOENZYME; LY 379196; PACLITAXEL; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C ETA; PROTEIN KINASE C GAMMA; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; SCLEROPROTEIN; TUMOR SUPPRESSOR PROTEIN; UNINDEXED DRUG; VASCULOTROPIN; VINCRISTINE;

CANCER GROWTH; CELL CYCLE ARREST; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOPATHOLOGY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME SUBSTRATE; ENZYME SUBUNIT; EXPERIMENTAL RAT; HUMAN; HYDROPHOBICITY; HYPERGLYCEMIA; KIDNEY CARCINOMA; KIDNEY DISEASE; MITOCHONDRIAL RESPIRATION; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STREPTOZOCIN DIABETES; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

CARCINOMA, RENAL CELL; DIABETIC NEPHROPATHIES; HUMANS; ISOENZYMES; KIDNEY; KIDNEY NEOPLASMS; PROTEIN KINASE C;

EID: 33749118040     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2006.00673.x     Document Type: Review

References (50)

1. Ahmad FK, He Z, King GL. Molecular targets of diabetic cardiovascular complications. Curr. Drug Targets 2005; 6: 487-94.
2. Engers R, Mrzyk S, Springer E et al. Protein kinase C in human renal cell carcinomas: Role in invasion and differential isoenzyme expression. Br. J. Cancer 2000; 82: 1063-9.
3. Newton AC. Diacylglycerol's affair with protein kinase C turns 25. Trends Pharmacol. Sci. 2004; 25: 175-7.
4. Musashi M, Ota S, Shiroshita N. The role of protein kinase C isoforms in cell proliferation and apoptosis. Int. J. Hematol. 2000; 72: 12-19.
5. da Rocha AB, Mans DR, Regner A, Schwartsmann G. Targeting protein kinase C: New therapeutic opportunities against high-grade malignant gliomas? Oncologist 2002; 7: 17-33.
6. Webb B, Hirst S, Giembycz M. Protein kinase C isoenzymes: A review of their structure, regulation and role in regulating airway smooth muscle tone and mitogenesis Br. J. Pharmacol. 2000; 130: 1433-52.
7. Liu WS, Heckman CA. The sevenfold way of PKC regulation. Cell. Signal. 1998; 10: 529-42.
8. Sonnenburg ED, Gao T, Newton AC. The phosphoinositide dependent kinase, PDK-1, phosphorylates conventional protein kinase C isozymes by a mechanism that is independent of phosphoinositide-3-kinase. J. Biol. Chem. 2001; 276: 45289-97.
9. Dutil EM, Newton AC. Dual role of pseudosubstrate in the coordinated regulation of protein kinase C by phosphorylation and diacylglycerol. J. Biol. Chem. 2000; 275: 10697-701.
10. Gao T, Toker A, Newton AC. The carboxyl terminus of protein kinase C provides a switch to regulate its interaction with the phosphoinositide- dependent kinase, PDK-1. J. Biol. Chem. 2001; 276: 19588-96.
11. Behn-Krappa A, Newton AC. The hydrophobic phosphorylation motif of conventional protein kinase C is regulated by autophosphorylation. Curr. Biol. 1999; 9: 728-37.
12. Vermeulen K, Berneman ZN, Van Bockstaele DR. Cell cycle and apoptosis. Cell Prolif. 2003; 36: 165-75.
13. Geiger M, Wrulich OA, Jenny M, Schwaiger W, Grunicke HH, Uberall F. Defining the human targets of phorbol ester and diacylglycerol. Curr. Opin. Mol. Ther. 2003; 5: 631-41.
14. James RI, Menaya J, Hudson K et al. Role of protein kinase C in induction of gene expression and inhibition of cell proliferation by interferon-alpha. Eur. J. Biochem. 1992; 209: 813-22.
15. Ha H, Lee HB. Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney. Nephrology (Carlton) 2005; 10 (Suppl.): S7-10.
16. Phillips MR. Compartmentalized signalling of Ras. Biochem. Soc. Trans. 2005; 33: 657-61.
17. Dempsey EC, Newton AC, Mochly-Rosen D et al. Protein kinase C isozymes and the regulation of diverse cell responses. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000; 279: L429-38.
18. Meinhardt G, Roth J, Totok G. Protein kinase C activation modulates pro- and anti-apoptotic signaling pathways. Eur. J. Cell Biol. 2000; 79: 824-33.
19. Ruvolo PP, Deng X, Carr BK, May WS. A functional role for mitochondrial protein kinase C alpha in Bcl2 phosphorylation and suppression of apoptosis. J. Biol. Chem. 1998; 273: 25436-42.
20. Majewski M, Niebrowska-Skorsa M, Salomoni P et al. Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res. 1999; 59: 2815-19.
21. Powell CT, Brittis NJ, Stec D, Hug H, Heston WD, Fair WR. Persistent membrane translocation of protein kinase C alpha during 12-O- tetradecanoylphorbol-13-acetate induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differ. 1996; 7: 419-28.
22. Nowak G. PKC-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells. J. Biol. Chem. 2002; 277: 43377-88.
23. Allen TR, Krueger KD, Hunter WJ III, Agrawal DK. Evidence that insulin-like growth factor-1 requires protein kinase C-epsilon, PI3-kinase and mitogen-activated protein kinase pathways to protect human vascular smooth muscle cells from apoptosis. Immunol. Cell Biol. 2005; 83: 651-67.
24. Mizuno K, Noda K, Araki T et al. The proteolytic cleavage of PKC isotypes, which generates kinase and regulatory fragments, correlates with Fas-mediated and 12-O-tetradecanoyl-phorbol-13-acetate-induced apoptosis. Eur. J. Biochem. 1997; 250: 7-18.
25. Denning MF, Wang Y, Tibudan S, Alkan S, Nickoloff BJ, Qin JZ. Caspase activation and disruption of mitochondrial membrane potential during UV radiation-induced apoptosis of human keratinocytes requires activation of protein kinase C. Cell Death Differ. 2002; 9: 40-52.
26. Reyland ME, Anderson SM, Matassa AA, Barzen KA, Quissell DO. Protein kinase C δ is essential for etoposide-induced apoptosis in salivary acinar cells. J. Biol. Chem. 1999; 274: 19115-23.
27. Emoto Y, Manome Y, Meinhardt G et al. Proteolytic activation of protein kinase C δ by an ICE-like protease in apoptotic cells. EMBO J. 1995; 14: 6148-56.
28. Lu Z, Hornia A, Jiang YW, Zang Q, Ohno S, Foster DA. Tumour promotion by depleting cells of protein kinase C δ. Mol. Cell. Biol. 1997; 17: 3418-28.
29. Araki T, Hayashi M, Saruta T. Cloning and characterization of a novel gene promoting ureteric bud branching in the metanephros. Kidney Int. 2003; 64: 1968-77.
30. Lang D, Terstesse M, Dohle F et al. Protein kinase C (PKC) dependent induction of tissue factor (TF) by mesangial cells in response to inflammatory mediators and release during apoptosis. Br. J. Pharmacol. 2002; 137: 1116-24.
31. Tuttle KR, Johnson EC, Cooney SK et al. Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C. Kidney Int. 2005; 67: 953-68.
32. Inoguchi T, Nawata H. NAD(P)H oxidase activation: A potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome. Curr. Drug Targets 2005; 6: 495-501.
33. Derubertis FR, Craven PA. Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic nephropathy. Diabetes 1994; 43: 1-8.
34. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterisation of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J. Clin. Invest. 1997; 100: 115-26.
35. Kelly DJ, Zhang Y, Hepper C et al. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continues hypertension. Diabetes 2003; 52: 512-18.
36. Tuttle KR, Anderson PW. A novel potential therapy for diabetic nephropathy and vascular complications: Protein kinase C beta inhibition. Am. J. Kidney Dis. 2003; 42: 456-65.
37. Amiri F, Garcia R. Renal angiotensin II receptors and protein kinase C in diabetic rats: Effects of insulin and ACE inhibition. Am. J. Physiol. Renal Physiol. 2000; 278: F603-12.
38. Fields AP, Gustafson WC. Protein kinase C in disease: Cancer. Methods Mol. Biol. 2003; 233: 519-37.
39. Brenner W, Farber G, Herget T, Wiesner C, Hengstler JG, Thuroff JW. Protein kinase C eta is associated with progression of renal cell carcinoma (RCC). Anticancer Res. 2003; 23: 4001-6.
40. Pal S, Claffey KP, Cohen HT, Mukhopadhyay D. Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. J. Biol. Chem. 1998; 273: 26277-80.
41. Tanabe K, Campbell SC, Alexander JP et al. Molecular regulation of intercellular adhesion molecule 1 (ICAM-1) expression in renal cell carcinoma. Urol. Res. 1997; 25: 231-8.
42. Pal S, Claffey KP, Dvorak HF, Mukhopadhyay D. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J. Biol. Chem. 1997; 272: 27509-12.
43. Basu A, Weixel K, Saijo N. Characterization of the protein kinase C signal transduction pathway in Cisplatin-sensitive and -resistant human small cell lung carcinoma cells. Cell Growth Differ. 1996; 7: 1507-12.
44. Fine RL, Chambers TG, Sachs CW. P-glycoprotein, multidrug resistance and protein kinase C. Oncologist 1996; 1: 261-8.
45. Chaudhary PM, Roninson IB. Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists. Oncol. Res. 1992; 4: 281-90.
46. Williams ME, Tuttle KR. The next generation of diabetic nephropathy therapies: An update. Adv. Chronic Kidney Dis. 2005; 12: 212-22.
47. Bohlen HG, Nase GP, Jin JS. Multiple mechanisms of early hyperglycaemic injury of the rat intestinal microcirculation. Clin. Exp. Pharmacol. Physiol. 2002; 29: 138-42.
48. Brenner W, Benzing F, Gudejko-Thiel J et al. Regulation of beta1 integrin expression by PKCepsilon in renal cancer cells. Int. J. Oncol. 2004; 25: 1157-63.
49. Swannie HC, Kaye SB. Protein kinase C inhibitors. Curr. Oncol. Rep. 2002; 4: 37-46.
50. Svensson K, Larsson C. A protein kinase C-beta inhibitor attenuates multidrug resistance of neuroblastoma cells. BMC Cancer 2003; 3: 10.